News & Updates

Philly Fights Cancer Honored at Phila Business Journal’s 2023 Faces of Philanthropy Awards

Saturday, April 15, 2023

Every April, the Philadelphia Business Journal recognizes the many incredible partnerships with local businesses and nonprofits that have collaborated to make a difference in our region with their Faces of Philanthropy awards.  Nominations for this honor are made by the public and the winners are selected by the editorial board of the Journal.

This year, there were double the number of nominations than in past years.  Philly Fights Cancer and Penn Medicine were nominated this year. We are so proud that we were found to be one of 30 nonprofits to receive this award.  The ceremony was held Thursday, April 13th at Rivers Casino and accepted by one of our amazing Philly Fights Cancer Committee Co-chairs, Missy Dietz.  Missy commented that, “I am so proud of what we have been able to accomplish over the  past 5 years and it is such an honor for us to be recognized in the community.”

Click here to read the full article:

https://www.bizjournals.com/philadelphia/news/2023/04/17/business-journal-faces-of-philanthropy-2023-photos.html

 

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Every April, the Philadelphia Business Journal recognizes the many incredible partnerships with local businesses and nonprofits that have collaborated to make a difference in our region with their Faces of Philanthropy awards.  Nominations for this honor are made by the public and the winners are selected by the editorial board of the Journal.

This year, there were double the number of nominations than in past years.  Philly Fights Cancer and Penn Medicine were nominated this year. We are so proud that we were found to be one of 30 nonprofits to receive this award.  The ceremony was held Thursday, April 13th at Rivers Casino and accepted by one of our amazing Philly Fights Cancer Committee Co-chairs, Missy Dietz.  Missy commented that, “I am so proud of what we have been able to accomplish over the  past 5 years and it is such an honor for us to be recognized in the community.”

Click here to read the full article:

https://www.bizjournals.com/philadelphia/news/2023/04/17/business-journal-faces-of-philanthropy-2023-photos.html

 

News & Updates

Philly Fights Cancer: Round 6 Starring The Roots, Daryl Hall, Kathy Sledge, and Amos Lee

Tuesday, March 21, 2023

Philly Fights Cancer: Round 6, An Evening with Philadelphia Legends will feature 3-time Grammy-winning band The Roots, Rock and Roll Hall of Fame Inductee Daryl Hall, Grammy-nominated singer-songwriter Kathy Sledge, and #1 Billboard chart-topper Amos Lee. The evening will also feature a special after-party performance by DJ Questlove. Together we will honor the legacy of Philadelphia-born philanthropist, visionary, and Philly Fights Cancer founder, Madlyn Abramson with a lineup of renowned musical talent from the City of Brotherly Love.

About The Roots

The legendary Roots Crew have become one of the best known and most respected hip-hop acts in the business, winning four GRAMMYS, including "Best R&B Album" for Wake Up!, "Best Traditional R&B Vocal Performance" for "Hang in There" (with John Legend) and "Best Group or Duo R&B Vocal Performance" for "Shine." This brings the band's GRAMMY nomination count to twelve. Additionally, "The Roots Picnic," a yearly star-studded mix of musicians, has become a celebrated institution. The Roots were named one of the greatest live bands around by Rolling Stone and serve as the official house band on The Tonight Show Starring Jimmy Fallon.

About Daryl Hall

Daryl Hall is a modern-day renaissance man, an inductee into the Rock and Roll Hall of Fame with the best-selling duo of all time, the star of his very own award-winning web series-turned-TV staple, Live from Daryl’s House, as well as a successful venue owner with “Daryl’s House,” a restored venue and live music space in Pawling, N.Y.

Since forming his partnership with John Oates in 1972, the Philadelphia soul man is still achieving career milestones more than four decades later, continuing to perform with his band to sold out venues everywhere.

It’s been quite a few years for Hall, including the opening of “Daryl’s House,” a combination world-class restaurant and performance venue, which he kicked off with a live-streamed Daryl Hall & John Oates concert on October 31, 2014 . The popular venue also serves as home base for his multi award-winning Live from Daryl’s House. The show, which began as a “light bulb” moment for Hall when he launched it in 2007 as a free webcast, has set the standard for artist-initiated projects. The groundbreaking series provides a mix of legends and the next generation of superstars.

Previous episodes of Live From Daryl’s House have featured a diverse mix of veteran and new performers from rock, soul, country and R&B including rock legends Sammy Hagar, Joe Walsh, Cheap Trick, Kenny Loggins, Todd Rundgren, Nick Lowe, Dave Stewart and Billy Gibbons of ZZ Top; soul and R&B artists The O’Jays, Aaron Neville, Aloe Blacc, Kandace Springs, Elle King, Wyclef Jean, Smokey Robinson, Cee Lo Green, Booker T & The MGs, and Sharon Jones; big-league singer/songwriters such as Ben Folds, Rob Thomas, Jason Mraz, Gavin DeGraw, Goo Goo Dolls’John Rzeznik and Fall Out Boy’s Patrick Stump; country artists such as Shelby Lynne; and has helped break new acts like Fitz & The Tantrums, Grace Potter & The Nocturnals, Neon Trees, Johnnyswim, Parachute and Anderson East.

Daryl Hall has come a long way, and he’s still got plenty of mileage left in a career that’s taken him from the streets of Philadelphia to the halls of the Rock and Roll Hall of Fame in Cleveland. The best is yet to come.

About Kathy Sledge

Kathy Sledge is a Renaissance woman — a singer, songwriter, author, producer, manager, and Grammy-nominated music icon whose boundless creativity and passion has garnered praise from critics and a legion of fans from all over the world. Her artistic triumphs encompass chart-topping hits, platinum albums, and successful forays into several genres of popular music. Through her multi-faceted music career and her legacy as the signature voice in Sister Sledge who originated worldwide anthems like "We Are Family," which was added to the Library of Congress' National Recording Registry in 2017, and "He's the Greatest Dancer," Kathy's inspired millions of listeners across every generation.

Iconic producer Nile Rodgers says it best: "Kathy has one of the most original and unique voices in pop music. Always has and always will!” While Kathy Sledge has tapped into the power of her voice, she consistently sets new standards of excellence. As a dynamic live performer, she's also developing her passion for producing shows for the stage and screen. Presently, she’s producing several live concerts and headlining festivals worldwide. She conceived both The Brighter Side of Day- A Billie Holiday Tribute and "Kathy Sledge presents: My Sisters & Me," a Classic Concert series that features "Sisters In Song”, Deniece Williams, Karyn White, and CeCe Peniston. With an impressive stylistic versatility, Kathy remains a vibrant presence in nearly every genre of popular music.

As one of the most sought-after voices in dance and pop music Kathy collaborated with renowned London-based production team Horse Meat Disco on recent chart-topping club hits "Jump Into the Light" (2020) and "Falling Deep in Love" (2019). Kathy received the "Outstanding Contribution Award" at the highly acclaimed Ibiza DJ Awards. "Music is my passion," she declares. "It's what I love to do, throughout my music career, and now more than ever.

About Amos Lee

With one foot in the real world and the other in a charmed dimension of his own making, Amos Lee creates the rare kind of music that’s emotionally raw yet touched with a certain magical quality. On his eighth album Dreamland, the Philadelphia-born singer/songwriter intimately documents his real-world struggles (alienation, anxiety, loneliness, despair), an outpouring born from deliberate and often painful self-examination. “For most of my life I’ve walked into rooms thinking, ‘I don’t belong here,’” says Lee. “I’ve come to the realization that I’m too comfortable as an isolated person, and I want to reach out more. This record came from questioning my connections to other people, to myself, to my past and to the future.”

In the spirit of fostering connection, Lee made Dreamland in close collaboration with L.A.-based producer Christian “Leggy” Langdon (Banks, Meg Myers). “I met with Leggy, who I really didn’t know anything about, and before we even started to work we had a very open and vulnerable conversation about what was going on in our lives,” he recalls. “So much of what I do is solitary work, and it felt good to find someone I could connect with—sort of like, ‘I’m a lonely kid, and I wanna play.’” Thanks to that palpable sense of playfulness, Dreamland embodies an unpredictable and endlessly imaginative sound—a prime showcase for Lee’s warmly commanding voice and soul-baring songwriting.

The very first song that Lee and Langdon created together, “Hold You” set the standard for Dreamland’s open-hearted confession. With its delicate convergence of so many exquisite sonic details—luminous guitar tones, ethereal textures, tender toy-piano melodies—the track finds Lee looking inward and uncovering a deep urge to provide comfort and solace. “Especially if you’ve grown up with a less-than-appealing inner voice, you have to start with yourself,” he notes.

On “Worry No More”—the mantra-like lead single to Dreamland—Lee shares his hard-won insight into riding out anxiety. “I’ve had a lot of episodes with anxiety in my life and now I feel much more equipped to handle them, partly because my family and friends have always been so supportive of me,” he says. “Music has also been so healing for me, and helped me to find a place in my mind that isn’t purely controlled by fear.” To that end, “Worry No More” gently exalts music’s power to brighten our perspective, with the song’s narrator slipping into a headphone-induced reverie as they wander a broken world (“I’m listening to the sounds of Miles/Spanish sketches, playground smiles/Crowded streets and empty vials/For all to share”).

All throughout Dreamland, Lee embraces an unfettered honesty, repeatedly shedding light on the darkest corners of his psyche. On “Into the Clearing,” for instance, the album takes on a moody intensity as Lee speaks to a desire for obliteration. “There’s always a longing to be one with the universe, to be one with nature, to be one with the sky,” he says. “And sometimes the only way you can be with the sky is to be smoke.” A powerfully uplifting track with a gospel-like energy, “See the Light” evokes a fierce resolve to hold tight to hope (“Since I know I’m going to be singing these songs over and over, I like to infuse them with helpful messages to myself,” Lee says). With its soulful piano work and soaring string arrangement, “Seeing Ghosts” reflects on anxiety’s insidious ability to warp our perception. “For a lot of people with anxiety disorders, there’s this fog that sets in, where your brain becomes overwhelmed and you disconnect,” says Lee. “I’ve definitely seen ghosts my whole life.” In a striking tonal shift, Lee then delivers one of Dreamland’s most euphoric moments on “Shoulda Known Better,” a radiant piece of R&B-pop fueled by his dreamy falsetto. “That song’s looking at the messy side of life,” he says. “It’s saying, ‘I was dumb, I shouldn’t have done that, but we had a lot of fun. I don’t regret it at all.’”

In the making of Dreamland, Lee found his songwriting indelibly informed by his recent reading of Johann Hari’s 2018 book Lost Connections. “It’s about depression, which I have a pretty deep history with, and how our society and our generation looks at mental health and healing in terms of medication rather than thinking about our personal relationship to the people and the world around us,” he says. And with the release of Dreamland, Lee hopes that his songs might inspire others to live more fully and free of fear. “Over the course of my life I’ve come to understand that music is my bridge to other people,” he says. “I have no idea what the waters are like below that bridge—it might be lava for all I know—but music allows me to float over the whole thing and connect. To me that’s the whole point of why we do this: to give people something to listen to and be enveloped by the love of another human being, and just be reminded that humanity is beautiful.”

Limited sponsorships remain for Philly Fights Cancer: Round 6. Contact sponsorships@phillyfightscancer.com for more information. We can’t wait to see you!

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Philly Fights Cancer: Round 6, An Evening with Philadelphia Legends will feature 3-time Grammy-winning band The Roots, Rock and Roll Hall of Fame Inductee Daryl Hall, Grammy-nominated singer-songwriter Kathy Sledge, and #1 Billboard chart-topper Amos Lee. The evening will also feature a special after-party performance by DJ Questlove. Together we will honor the legacy of Philadelphia-born philanthropist, visionary, and Philly Fights Cancer founder, Madlyn Abramson with a lineup of renowned musical talent from the City of Brotherly Love.

About The Roots

The legendary Roots Crew have become one of the best known and most respected hip-hop acts in the business, winning four GRAMMYS, including "Best R&B Album" for Wake Up!, "Best Traditional R&B Vocal Performance" for "Hang in There" (with John Legend) and "Best Group or Duo R&B Vocal Performance" for "Shine." This brings the band's GRAMMY nomination count to twelve. Additionally, "The Roots Picnic," a yearly star-studded mix of musicians, has become a celebrated institution. The Roots were named one of the greatest live bands around by Rolling Stone and serve as the official house band on The Tonight Show Starring Jimmy Fallon.

About Daryl Hall

Daryl Hall is a modern-day renaissance man, an inductee into the Rock and Roll Hall of Fame with the best-selling duo of all time, the star of his very own award-winning web series-turned-TV staple, Live from Daryl’s House, as well as a successful venue owner with “Daryl’s House,” a restored venue and live music space in Pawling, N.Y.

Since forming his partnership with John Oates in 1972, the Philadelphia soul man is still achieving career milestones more than four decades later, continuing to perform with his band to sold out venues everywhere.

It’s been quite a few years for Hall, including the opening of “Daryl’s House,” a combination world-class restaurant and performance venue, which he kicked off with a live-streamed Daryl Hall & John Oates concert on October 31, 2014 . The popular venue also serves as home base for his multi award-winning Live from Daryl’s House. The show, which began as a “light bulb” moment for Hall when he launched it in 2007 as a free webcast, has set the standard for artist-initiated projects. The groundbreaking series provides a mix of legends and the next generation of superstars.

Previous episodes of Live From Daryl’s House have featured a diverse mix of veteran and new performers from rock, soul, country and R&B including rock legends Sammy Hagar, Joe Walsh, Cheap Trick, Kenny Loggins, Todd Rundgren, Nick Lowe, Dave Stewart and Billy Gibbons of ZZ Top; soul and R&B artists The O’Jays, Aaron Neville, Aloe Blacc, Kandace Springs, Elle King, Wyclef Jean, Smokey Robinson, Cee Lo Green, Booker T & The MGs, and Sharon Jones; big-league singer/songwriters such as Ben Folds, Rob Thomas, Jason Mraz, Gavin DeGraw, Goo Goo Dolls’John Rzeznik and Fall Out Boy’s Patrick Stump; country artists such as Shelby Lynne; and has helped break new acts like Fitz & The Tantrums, Grace Potter & The Nocturnals, Neon Trees, Johnnyswim, Parachute and Anderson East.

Daryl Hall has come a long way, and he’s still got plenty of mileage left in a career that’s taken him from the streets of Philadelphia to the halls of the Rock and Roll Hall of Fame in Cleveland. The best is yet to come.

About Kathy Sledge

Kathy Sledge is a Renaissance woman — a singer, songwriter, author, producer, manager, and Grammy-nominated music icon whose boundless creativity and passion has garnered praise from critics and a legion of fans from all over the world. Her artistic triumphs encompass chart-topping hits, platinum albums, and successful forays into several genres of popular music. Through her multi-faceted music career and her legacy as the signature voice in Sister Sledge who originated worldwide anthems like "We Are Family," which was added to the Library of Congress' National Recording Registry in 2017, and "He's the Greatest Dancer," Kathy's inspired millions of listeners across every generation.

Iconic producer Nile Rodgers says it best: "Kathy has one of the most original and unique voices in pop music. Always has and always will!” While Kathy Sledge has tapped into the power of her voice, she consistently sets new standards of excellence. As a dynamic live performer, she's also developing her passion for producing shows for the stage and screen. Presently, she’s producing several live concerts and headlining festivals worldwide. She conceived both The Brighter Side of Day- A Billie Holiday Tribute and "Kathy Sledge presents: My Sisters & Me," a Classic Concert series that features "Sisters In Song”, Deniece Williams, Karyn White, and CeCe Peniston. With an impressive stylistic versatility, Kathy remains a vibrant presence in nearly every genre of popular music.

As one of the most sought-after voices in dance and pop music Kathy collaborated with renowned London-based production team Horse Meat Disco on recent chart-topping club hits "Jump Into the Light" (2020) and "Falling Deep in Love" (2019). Kathy received the "Outstanding Contribution Award" at the highly acclaimed Ibiza DJ Awards. "Music is my passion," she declares. "It's what I love to do, throughout my music career, and now more than ever.

About Amos Lee

With one foot in the real world and the other in a charmed dimension of his own making, Amos Lee creates the rare kind of music that’s emotionally raw yet touched with a certain magical quality. On his eighth album Dreamland, the Philadelphia-born singer/songwriter intimately documents his real-world struggles (alienation, anxiety, loneliness, despair), an outpouring born from deliberate and often painful self-examination. “For most of my life I’ve walked into rooms thinking, ‘I don’t belong here,’” says Lee. “I’ve come to the realization that I’m too comfortable as an isolated person, and I want to reach out more. This record came from questioning my connections to other people, to myself, to my past and to the future.”

In the spirit of fostering connection, Lee made Dreamland in close collaboration with L.A.-based producer Christian “Leggy” Langdon (Banks, Meg Myers). “I met with Leggy, who I really didn’t know anything about, and before we even started to work we had a very open and vulnerable conversation about what was going on in our lives,” he recalls. “So much of what I do is solitary work, and it felt good to find someone I could connect with—sort of like, ‘I’m a lonely kid, and I wanna play.’” Thanks to that palpable sense of playfulness, Dreamland embodies an unpredictable and endlessly imaginative sound—a prime showcase for Lee’s warmly commanding voice and soul-baring songwriting.

The very first song that Lee and Langdon created together, “Hold You” set the standard for Dreamland’s open-hearted confession. With its delicate convergence of so many exquisite sonic details—luminous guitar tones, ethereal textures, tender toy-piano melodies—the track finds Lee looking inward and uncovering a deep urge to provide comfort and solace. “Especially if you’ve grown up with a less-than-appealing inner voice, you have to start with yourself,” he notes.

On “Worry No More”—the mantra-like lead single to Dreamland—Lee shares his hard-won insight into riding out anxiety. “I’ve had a lot of episodes with anxiety in my life and now I feel much more equipped to handle them, partly because my family and friends have always been so supportive of me,” he says. “Music has also been so healing for me, and helped me to find a place in my mind that isn’t purely controlled by fear.” To that end, “Worry No More” gently exalts music’s power to brighten our perspective, with the song’s narrator slipping into a headphone-induced reverie as they wander a broken world (“I’m listening to the sounds of Miles/Spanish sketches, playground smiles/Crowded streets and empty vials/For all to share”).

All throughout Dreamland, Lee embraces an unfettered honesty, repeatedly shedding light on the darkest corners of his psyche. On “Into the Clearing,” for instance, the album takes on a moody intensity as Lee speaks to a desire for obliteration. “There’s always a longing to be one with the universe, to be one with nature, to be one with the sky,” he says. “And sometimes the only way you can be with the sky is to be smoke.” A powerfully uplifting track with a gospel-like energy, “See the Light” evokes a fierce resolve to hold tight to hope (“Since I know I’m going to be singing these songs over and over, I like to infuse them with helpful messages to myself,” Lee says). With its soulful piano work and soaring string arrangement, “Seeing Ghosts” reflects on anxiety’s insidious ability to warp our perception. “For a lot of people with anxiety disorders, there’s this fog that sets in, where your brain becomes overwhelmed and you disconnect,” says Lee. “I’ve definitely seen ghosts my whole life.” In a striking tonal shift, Lee then delivers one of Dreamland’s most euphoric moments on “Shoulda Known Better,” a radiant piece of R&B-pop fueled by his dreamy falsetto. “That song’s looking at the messy side of life,” he says. “It’s saying, ‘I was dumb, I shouldn’t have done that, but we had a lot of fun. I don’t regret it at all.’”

In the making of Dreamland, Lee found his songwriting indelibly informed by his recent reading of Johann Hari’s 2018 book Lost Connections. “It’s about depression, which I have a pretty deep history with, and how our society and our generation looks at mental health and healing in terms of medication rather than thinking about our personal relationship to the people and the world around us,” he says. And with the release of Dreamland, Lee hopes that his songs might inspire others to live more fully and free of fear. “Over the course of my life I’ve come to understand that music is my bridge to other people,” he says. “I have no idea what the waters are like below that bridge—it might be lava for all I know—but music allows me to float over the whole thing and connect. To me that’s the whole point of why we do this: to give people something to listen to and be enveloped by the love of another human being, and just be reminded that humanity is beautiful.”

Limited sponsorships remain for Philly Fights Cancer: Round 6. Contact sponsorships@phillyfightscancer.com for more information. We can’t wait to see you!

News & Updates

Four distinguished researchers from the Abramson Cancer Center will receive Scientific Achievement Awards

Wednesday, March 15, 2023

Four distinguished researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will receive 2023 Scientific Achievement Awards from the American Association for Cancer Research (AACR), the world’s oldest and largest cancer research organization. Carl H. June, MD, who is recognized for his pioneering role in the development of CAR T cell therapy for cancer, which uses modified versions of patients' own immune cells to attack their cancer, and was funded by Madlyn and Leonard Abramson, will present at the awards.

  1. Celeste Simon, PhD, is the recipient of the Clowes Award for Outstanding Basic Cancer Research. Kathryn E. Wellen, PhD, a professor and the vice chair of Cancer Biology, will receive the award for Outstanding Achievement in Basic Cancer Research. E. John Wherry, PhD, the chair of Systems Pharmacology and Translational Therapeutics, will receive the Lloyd J. Old Award in Cancer Immunology.

“We are thrilled to see so many researchers from Penn Medicine’s Abramson Cancer Center recognized by AACR for the incredible impacts that they’ve made across the spectrum of basic, translational and clinical cancer research,” said Katherine L. Nathanson, MD, the Pearl Basser Professor for BRCA-Related Research, deputy director of the Abramson Cancer Center (ACC), and head of the ACC Awards Committee.

Click here to read the full article:

https://www.pennmedicine.org/news/news-releases/2023/april/four-abramson-cancer-center-researchers-receive-top-aacr-awards

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Four distinguished researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will receive 2023 Scientific Achievement Awards from the American Association for Cancer Research (AACR), the world’s oldest and largest cancer research organization. Carl H. June, MD, who is recognized for his pioneering role in the development of CAR T cell therapy for cancer, which uses modified versions of patients' own immune cells to attack their cancer, and was funded by Madlyn and Leonard Abramson, will present at the awards.

  1. Celeste Simon, PhD, is the recipient of the Clowes Award for Outstanding Basic Cancer Research. Kathryn E. Wellen, PhD, a professor and the vice chair of Cancer Biology, will receive the award for Outstanding Achievement in Basic Cancer Research. E. John Wherry, PhD, the chair of Systems Pharmacology and Translational Therapeutics, will receive the Lloyd J. Old Award in Cancer Immunology.

“We are thrilled to see so many researchers from Penn Medicine’s Abramson Cancer Center recognized by AACR for the incredible impacts that they’ve made across the spectrum of basic, translational and clinical cancer research,” said Katherine L. Nathanson, MD, the Pearl Basser Professor for BRCA-Related Research, deputy director of the Abramson Cancer Center (ACC), and head of the ACC Awards Committee.

Click here to read the full article:

https://www.pennmedicine.org/news/news-releases/2023/april/four-abramson-cancer-center-researchers-receive-top-aacr-awards

News & Updates

Philly Fights Cancer: Round 6 Ad Book Tribute Information

Friday, February 17, 2023

Philly Fights Cancer Round 6 is fast approaching! May 20th is just around the corner.  We are thrilled to finally be back after a 3 year break due to Covid.  This incredible event will be held at The Fillmore and will honor Madlyn Abramson who sadly passed away in April of 2020. An important part of this special event is the beautiful Tribute Book.

Madlyn was instrumental in ensuring that all patients at the Abramson Cancer Center receive state of the art medical care and personalized attention. Attached you can see the various tribute book opportunities, including a special “Tribute” section where you can honor Madlyn Abramson, a family member or friend who has battled or is still battling cancer. This year, Philly Fights Cancer will help advance the Sarcoma program and continue the support of translational research and clinical trials at the Abramson Cancer Center.  If you have any questions, please reach out to Bonnie Weinberger at bonnie.weinberger@pennmedicine.upenn.edu.

To download the Tribute Book form, click here.

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Philly Fights Cancer Round 6 is fast approaching! May 20th is just around the corner.  We are thrilled to finally be back after a 3 year break due to Covid.  This incredible event will be held at The Fillmore and will honor Madlyn Abramson who sadly passed away in April of 2020. An important part of this special event is the beautiful Tribute Book.

Madlyn was instrumental in ensuring that all patients at the Abramson Cancer Center receive state of the art medical care and personalized attention. Attached you can see the various tribute book opportunities, including a special “Tribute” section where you can honor Madlyn Abramson, a family member or friend who has battled or is still battling cancer. This year, Philly Fights Cancer will help advance the Sarcoma program and continue the support of translational research and clinical trials at the Abramson Cancer Center.  If you have any questions, please reach out to Bonnie Weinberger at bonnie.weinberger@pennmedicine.upenn.edu.

To download the Tribute Book form, click here.

News & Updates

Prevent Breast Cancer: Translational Center of Excellence

Wednesday, January 25, 2023

Continuing the theme of Translational Centers of Excellence (TCE’s), Penn started these Centers at Penn Medicine's Abramson Cancer Center so that flagship medical programs could be created.  These Centers bring together experts from diverse fields in cancer research to address major challenges in cancer care facing the world today.

Faculty from the Penn community were invited to form teams and develop multidisciplinary, disease-specific Centers to try to find solutions to the most pressing issues confronting cancer patients.  These Centers will hopefully accelerate the pace of discoveries that will help today's patients become — and stay — cancer-free.  Everyone from scientists and engineers to medical doctors have been brought together to help eradicate cancer completely.

Last month, our focus was the Ovarian Cancer TCE.  This month we will focus on the 2-Prevent Breast Cancer: Translational Center of Excellence.  We are incredibly fortunate that so many people beat breast cancer these days, but it is important to recognize that 30% of people do relapse in addition to having late treatment effects. Our 2-PREVENT Breast Cancer Translational Center of Excellence is the only program in the country with a focus on preventing, identifying, and treating the issues that may arise after the initial treatment for breast cancer.

Research plays a vital role in preventing, identifying and treating relapsed breast cancer. Penn Medicine’s investigators study all parts of the disease to determine the best preventative care and treatment.  The areas of research include cancer cell detection, genomic testing, immunotherapy, and screening for late treatment effects.

Read more about this potential new treatment strategy from Penn Medicine here: https://www.pennmedicine.org/cancer/cancer-research/translating-research-to-practice/ovarian-cancer-tce

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Continuing the theme of Translational Centers of Excellence (TCE’s), Penn started these Centers at Penn Medicine's Abramson Cancer Center so that flagship medical programs could be created.  These Centers bring together experts from diverse fields in cancer research to address major challenges in cancer care facing the world today.

Faculty from the Penn community were invited to form teams and develop multidisciplinary, disease-specific Centers to try to find solutions to the most pressing issues confronting cancer patients.  These Centers will hopefully accelerate the pace of discoveries that will help today's patients become — and stay — cancer-free.  Everyone from scientists and engineers to medical doctors have been brought together to help eradicate cancer completely.

Last month, our focus was the Ovarian Cancer TCE.  This month we will focus on the 2-Prevent Breast Cancer: Translational Center of Excellence.  We are incredibly fortunate that so many people beat breast cancer these days, but it is important to recognize that 30% of people do relapse in addition to having late treatment effects. Our 2-PREVENT Breast Cancer Translational Center of Excellence is the only program in the country with a focus on preventing, identifying, and treating the issues that may arise after the initial treatment for breast cancer.

Research plays a vital role in preventing, identifying and treating relapsed breast cancer. Penn Medicine’s investigators study all parts of the disease to determine the best preventative care and treatment.  The areas of research include cancer cell detection, genomic testing, immunotherapy, and screening for late treatment effects.

Read more about this potential new treatment strategy from Penn Medicine here: https://www.pennmedicine.org/cancer/cancer-research/translating-research-to-practice/ovarian-cancer-tce

News & Updates

Translational Centers of Excellence: Ovarian Cancer

Tuesday, December 20, 2022

Translational Centers of Excellence (TCE’s) were started at Penn Medicine's Abramson Cancer Center so that flagship medical programs could be created.  These Centers bring together experts from diverse fields in cancer research to address major challenges in cancer care facing the world today.

Faculty from the Penn community were invited to form teams and develop multidisciplinary, disease-specific Centers to try to find solutions to the most pressing issues confronting cancer patients.  These Centers will hopefully accelerate the pace of discoveries that will help today's patients become — and stay — cancer-free.  Everyone from scientists and engineers, to medical doctors,  have been brought together to help eradicate cancer completely.

One of the TCE’s formed is the Ovarian Cancer TCE.  They are working to transform ovarian cancer by bridging the gap that sometimes occurs between research and patient care and what is being developed in the lab versus what the patients receive when cared for in the clinic or hospital. The goal is to provide new therapeutic options to patients being treated for, in this instance, ovarian cancer. The TCE bridge will make it easier than ever before, to rapidly translate new laboratory findings into clinical practice and allow us to provide patients with new therapeutic options.

Tumor Banking is when living tumor tissue is collected from patients cared for by gynecologic oncologists.  Tumor samples are currently being collected when an initial diagnosis is made or there is a recurrence of the cancer is found.  The samples become part of the Ovarian Cancer Research Center (OCRC) Tumor Biotrust and are used to study how ovarian cancer evolves over time with the goal of discovering more effective treatment options.

Read more about this potential new treatment strategy from Penn Medicine here: https://www.pennmedicine.org/cancer/cancer-research/translating-research-to-practice/ovarian-cancer-tce

 

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Translational Centers of Excellence (TCE’s) were started at Penn Medicine's Abramson Cancer Center so that flagship medical programs could be created.  These Centers bring together experts from diverse fields in cancer research to address major challenges in cancer care facing the world today.

Faculty from the Penn community were invited to form teams and develop multidisciplinary, disease-specific Centers to try to find solutions to the most pressing issues confronting cancer patients.  These Centers will hopefully accelerate the pace of discoveries that will help today's patients become — and stay — cancer-free.  Everyone from scientists and engineers, to medical doctors,  have been brought together to help eradicate cancer completely.

One of the TCE’s formed is the Ovarian Cancer TCE.  They are working to transform ovarian cancer by bridging the gap that sometimes occurs between research and patient care and what is being developed in the lab versus what the patients receive when cared for in the clinic or hospital. The goal is to provide new therapeutic options to patients being treated for, in this instance, ovarian cancer. The TCE bridge will make it easier than ever before, to rapidly translate new laboratory findings into clinical practice and allow us to provide patients with new therapeutic options.

Tumor Banking is when living tumor tissue is collected from patients cared for by gynecologic oncologists.  Tumor samples are currently being collected when an initial diagnosis is made or there is a recurrence of the cancer is found.  The samples become part of the Ovarian Cancer Research Center (OCRC) Tumor Biotrust and are used to study how ovarian cancer evolves over time with the goal of discovering more effective treatment options.

Read more about this potential new treatment strategy from Penn Medicine here: https://www.pennmedicine.org/cancer/cancer-research/translating-research-to-practice/ovarian-cancer-tce

 

News & Updates

Perelman School of Medicine Finds Potential New Treatment Strategy for Liver Cancer Patients

Tuesday, November 15, 2022

Hepatocellular Carcinoma (HCC) is the most typical type of liver cancer in adults. According to the National Cancer Institute, it is to blame for 80% of primary liver tumors, or malignancies that start in the liver rather than spread there from other organs. Worldwide, there have been around a million occurrences of HCC, and every year, about 29,000 Americans are given the diagnosis. The main known causes of HCC are thought to include chronic liver inflammation, obesity, and alcoholism. The disease is rarely treated since it is often only discovered once it has advanced past the point at which surgical removal is still a possibility. Furthermore, liver transplants, which can alleviate benign illness, frequently may not be available to persons with severe HCC. There are hardly many pharmacological treatments therapy for HCC, and they almost never succeed in curing the condition. Thus, the urgent need for new therapeutic approaches.

A study from the Perelman School of Medicine at the University of Pennsylvania found that liver cancer's quick growth creates a vulnerability in its energy-production and cell-building processes that may be successfully exploited utilizing a new combination-treatment method. In August, scientists discovered that hepatocellular carcinoma (HCC), the most prevalent type of primary liver cancer, modifies its metabolism in a way that leaves it vulnerable to reductions in the availability of an essential substance called arginine. They found that this arginine vulnerability was present in every single HCC tumor, regardless of the specific genetic alterations that gave rise to each tumor.

The researchers showed in preclinical trials that arginine deprivation leads HCC tumors to enter a non-growing stage while preventing the survival-promoting response that results. In this condition, a new class of medications that specifically target senescent cells can successfully eradicate the tumors.

Read more about this potential new treatment strategy from Penn Medicine here: https://www.pennmedicine.org/news/news-releases/2022/august/liver-cancer-supercharged-metabolism-offers-a-new-treatment-strategy-penn-study-suggests

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Hepatocellular Carcinoma (HCC) is the most typical type of liver cancer in adults. According to the National Cancer Institute, it is to blame for 80% of primary liver tumors, or malignancies that start in the liver rather than spread there from other organs. Worldwide, there have been around a million occurrences of HCC, and every year, about 29,000 Americans are given the diagnosis. The main known causes of HCC are thought to include chronic liver inflammation, obesity, and alcoholism. The disease is rarely treated since it is often only discovered once it has advanced past the point at which surgical removal is still a possibility. Furthermore, liver transplants, which can alleviate benign illness, frequently may not be available to persons with severe HCC. There are hardly many pharmacological treatments therapy for HCC, and they almost never succeed in curing the condition. Thus, the urgent need for new therapeutic approaches.

A study from the Perelman School of Medicine at the University of Pennsylvania found that liver cancer's quick growth creates a vulnerability in its energy-production and cell-building processes that may be successfully exploited utilizing a new combination-treatment method. In August, scientists discovered that hepatocellular carcinoma (HCC), the most prevalent type of primary liver cancer, modifies its metabolism in a way that leaves it vulnerable to reductions in the availability of an essential substance called arginine. They found that this arginine vulnerability was present in every single HCC tumor, regardless of the specific genetic alterations that gave rise to each tumor.

The researchers showed in preclinical trials that arginine deprivation leads HCC tumors to enter a non-growing stage while preventing the survival-promoting response that results. In this condition, a new class of medications that specifically target senescent cells can successfully eradicate the tumors.

Read more about this potential new treatment strategy from Penn Medicine here: https://www.pennmedicine.org/news/news-releases/2022/august/liver-cancer-supercharged-metabolism-offers-a-new-treatment-strategy-penn-study-suggests

News & Updates

The Race to Make a Vaccine for Breast Cancer

Wednesday, October 19, 2022

Dr. Robert Vonderheide, Director of Penn Medicine’s Abramson Cancer Center, was recently quoted in an article from Time Magazine titled, “The Race to Make a Vaccine for Breast Cancer” where he discusses the latest in cancer vaccine research. Medical oncologists at Penn Medicine are internationally recognized for the use of vaccines to stimulate the immune system in the treatment of cancer. Cancer vaccines are used to treat cancers that have already developed, with the objective to delay or stop cancer cell growth, shrink tumors, prevent cancer from coming back and eliminate cancer cells that have not been killed by other forms of treatment.

From the Time Magazine article:

Vaccines are often called the miracle of modern medicine for their ability to target the immune system against disease-causing viruses and bacteria. Since they work against infectious diseases, why not against other conditions that have long plagued humanity—like cancer?

“To say that we are working on a vaccine to prevent cancers for the rest of people’s lives sounds like something from Star Wars,” says Dr. Robert Vonderheide, director of the Abramson Cancer Center at Penn Medicine. “But it’s not a concept that’s totally uncharted.”

The article continues:

Vaccines for cancer already exist. Human papillomavirus (HPV) vaccines, for example, largely prevent cervical cancer by targeting the HPV strains that trigger tumor growths. But most types of cancer aren’t caused by viruses, so the holy grail would be to train the body to recognize tumor cells instead. Researchers have been investigating ways to do this, starting with immunizing people who have already developed cancer in order to reduce their risk of recurrences. Improvements in the accuracy and speed of genetic sequencing have provided a clearer window into what makes cancer cells start to grow abnormally, and new drug therapies that target those genetic changes have also transformed the way doctors treat the disease. For instance, recently developed treatments can teach the immune system to seek out and destroy cancer cells.

To date, however, these immunotherapy treatments have been focused mostly on patients with advanced disease that has spread throughout their bodies, and vaccines to target those widespread cancer cells have generally been a last-resort effort to control the disease. Such therapeutic cancer vaccines remain a work in progress, but their limited success, along with new understanding of the genetic drivers behind cancer growth, have made the idea of a vaccine that could actually prevent cancer more realistic.

The full article from Time Magazine is available here (by Alice Park)

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Dr. Robert Vonderheide, Director of Penn Medicine’s Abramson Cancer Center, was recently quoted in an article from Time Magazine titled, “The Race to Make a Vaccine for Breast Cancer” where he discusses the latest in cancer vaccine research. Medical oncologists at Penn Medicine are internationally recognized for the use of vaccines to stimulate the immune system in the treatment of cancer. Cancer vaccines are used to treat cancers that have already developed, with the objective to delay or stop cancer cell growth, shrink tumors, prevent cancer from coming back and eliminate cancer cells that have not been killed by other forms of treatment.

From the Time Magazine article:

Vaccines are often called the miracle of modern medicine for their ability to target the immune system against disease-causing viruses and bacteria. Since they work against infectious diseases, why not against other conditions that have long plagued humanity—like cancer?

“To say that we are working on a vaccine to prevent cancers for the rest of people’s lives sounds like something from Star Wars,” says Dr. Robert Vonderheide, director of the Abramson Cancer Center at Penn Medicine. “But it’s not a concept that’s totally uncharted.”

The article continues:

Vaccines for cancer already exist. Human papillomavirus (HPV) vaccines, for example, largely prevent cervical cancer by targeting the HPV strains that trigger tumor growths. But most types of cancer aren’t caused by viruses, so the holy grail would be to train the body to recognize tumor cells instead. Researchers have been investigating ways to do this, starting with immunizing people who have already developed cancer in order to reduce their risk of recurrences. Improvements in the accuracy and speed of genetic sequencing have provided a clearer window into what makes cancer cells start to grow abnormally, and new drug therapies that target those genetic changes have also transformed the way doctors treat the disease. For instance, recently developed treatments can teach the immune system to seek out and destroy cancer cells.

To date, however, these immunotherapy treatments have been focused mostly on patients with advanced disease that has spread throughout their bodies, and vaccines to target those widespread cancer cells have generally been a last-resort effort to control the disease. Such therapeutic cancer vaccines remain a work in progress, but their limited success, along with new understanding of the genetic drivers behind cancer growth, have made the idea of a vaccine that could actually prevent cancer more realistic.

The full article from Time Magazine is available here (by Alice Park)

News & Updates

Personalized Immunotherapy Shows Promise Beyond Cancer

Tuesday, September 27, 2022

Last month, Philly Fights Cancer: Round 4 honoree, Time Magazine “Most Influential Person of the Year”, and Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at Penn Medicine Dr. Carl June was featured on podcast “Science Friday” to discuss the many ways in which personalized immunotherapy is revolutionizing what’s possible in cancer care.

CAR T cell therapy, a type of immunotherapy in which a patient’s own immune cells are modified to create a hybrid immune cell that destroys cancer cells, was first developed over a decade ago. Now, researchers are continuing to find success in treating new types of blood cancers with the therapy, and are working on applying the technology to solid state cancers like those of the pancreas and brain.  Scientists are also at the early stages of testing CAR T cells to treat autoimmune diseases like multiple sclerosis (MS) and lupus.

Philly Fights Cancer has been raising funding for translational research and clinical trials for CART T therapy since its inception in 2015. Clinical trials have been instrumental in the development and FDA approval of CAR T.

Science Friday host Ira Flatow talks with Dr. Carl June, one of the pioneers of CAR T cell therapy, a professor of immunotherapy and director of the Center for Cellular Immunotherapies at the University of Pennsylvania, based in Philadelphia.

The full episode can be heard here:
https://www.sciencefriday.com/segments/car-t-cell-therapy/

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

Last month, Philly Fights Cancer: Round 4 honoree, Time Magazine “Most Influential Person of the Year”, and Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine at Penn Medicine Dr. Carl June was featured on podcast “Science Friday” to discuss the many ways in which personalized immunotherapy is revolutionizing what’s possible in cancer care.

CAR T cell therapy, a type of immunotherapy in which a patient’s own immune cells are modified to create a hybrid immune cell that destroys cancer cells, was first developed over a decade ago. Now, researchers are continuing to find success in treating new types of blood cancers with the therapy, and are working on applying the technology to solid state cancers like those of the pancreas and brain.  Scientists are also at the early stages of testing CAR T cells to treat autoimmune diseases like multiple sclerosis (MS) and lupus.

Philly Fights Cancer has been raising funding for translational research and clinical trials for CART T therapy since its inception in 2015. Clinical trials have been instrumental in the development and FDA approval of CAR T.

Science Friday host Ira Flatow talks with Dr. Carl June, one of the pioneers of CAR T cell therapy, a professor of immunotherapy and director of the Center for Cellular Immunotherapies at the University of Pennsylvania, based in Philadelphia.

The full episode can be heard here:
https://www.sciencefriday.com/segments/car-t-cell-therapy/

News & Updates

Penn School of Medicine Finds Potential New Treatment Strategy for Liver Cancer Patients

Monday, August 15, 2022

According to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania, liver cancer's rapid development causes a vulnerability in its energy-production and cell-building processes that may be effectively exploited using a new combination-treatment technique. Researchers found in August that the most common form of primary liver cancer, hepatocellular carcinoma (HCC), alters its metabolism in a way that makes it vulnerable to interruptions in the availability of a crucial chemical, arginine. They discovered that regardless of the particular genetic changes giving rise to each HCC tumor, this arginine susceptibility was present in every single one of them.

In preclinical experiments, the researchers demonstrated that depriving HCC tumors of arginine and blocking the survival-promoting response that results causes HCC tumors to enter a non-growing, or "senescent," state. In this state, the tumors are susceptible to being eliminated by a new class of drugs that target senescent cells.

Celeste Simon, PhD, the Arthur H. Rubenstein, MBBCh Professor in the Department of Cell and Developmental Biology and Scientific Director of the Abramson Family Cancer Research Institute at Penn Medicine, was the study's senior author and recognized that she and her team had essentially “…identified a metabolic property of most liver cancers that offers the possibility of treating these cancers effectively, using drugs that are already approved or in development”.

The most common kind of liver cancer in adults is HCC. It is responsible for about 80% of primary liver tumors, or cancers that begin in the liver rather than spread there from other organs, according to the National Cancer Institute. Nearly a million cases of HCC have been reported worldwide, and roughly 29,000 Americans are diagnosed with it each year. Alcoholism, obesity, and chronic liver inflammation are known to be the main causes of HCC. Because the disease is typically detected only after it has progressed past the point where surgical removal is still an option, it is rarely treated. Furthermore, people with severe HCC frequently may not have access to liver transplants, which can treat benign illness. There are few drug therapies for HCC, and they practically never cure the disease. New therapy methods are thus desperately needed.

Read more about the specifics of this groundbreaking research on Penn Medicine News.

Want to stay informed?

Sign-up for Our Newsletter
for Philly Fights Cancer News.

Sign Up

According to a study from researchers at the Perelman School of Medicine at the University of Pennsylvania, liver cancer's rapid development causes a vulnerability in its energy-production and cell-building processes that may be effectively exploited using a new combination-treatment technique. Researchers found in August that the most common form of primary liver cancer, hepatocellular carcinoma (HCC), alters its metabolism in a way that makes it vulnerable to interruptions in the availability of a crucial chemical, arginine. They discovered that regardless of the particular genetic changes giving rise to each HCC tumor, this arginine susceptibility was present in every single one of them.

In preclinical experiments, the researchers demonstrated that depriving HCC tumors of arginine and blocking the survival-promoting response that results causes HCC tumors to enter a non-growing, or "senescent," state. In this state, the tumors are susceptible to being eliminated by a new class of drugs that target senescent cells.

Celeste Simon, PhD, the Arthur H. Rubenstein, MBBCh Professor in the Department of Cell and Developmental Biology and Scientific Director of the Abramson Family Cancer Research Institute at Penn Medicine, was the study's senior author and recognized that she and her team had essentially “…identified a metabolic property of most liver cancers that offers the possibility of treating these cancers effectively, using drugs that are already approved or in development”.

The most common kind of liver cancer in adults is HCC. It is responsible for about 80% of primary liver tumors, or cancers that begin in the liver rather than spread there from other organs, according to the National Cancer Institute. Nearly a million cases of HCC have been reported worldwide, and roughly 29,000 Americans are diagnosed with it each year. Alcoholism, obesity, and chronic liver inflammation are known to be the main causes of HCC. Because the disease is typically detected only after it has progressed past the point where surgical removal is still an option, it is rarely treated. Furthermore, people with severe HCC frequently may not have access to liver transplants, which can treat benign illness. There are few drug therapies for HCC, and they practically never cure the disease. New therapy methods are thus desperately needed.

Read more about the specifics of this groundbreaking research on Penn Medicine News.